ACM
WX

Apex Capital Management’s WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS WX Stock Holding History

Apex Capital Management’s Portfolio WX Stock Details WX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-1,723,714
Closed -$74.5M – 264
2015
Q3 		$74.5M Buy
1,723,714
+79,884
+5% +$3.37M 1.69% 9
2015
Q2 		$69.5M Buy
1,643,830
+105,963
+7% +$4.47M 1.49% 14
2015
Q1 		$59.6M Buy
1,537,867
+398,238
+35% +$15.3M 1.4% 19
2014
Q4 		$38.4M Buy
1,139,629
+91,098
+9% +$3.22M 1.02% 40
2014
Q3 		$36.7M Buy
1,048,531
+63,901
+6% +$2.19M 1.11% 36
2014
Q2 		$32.4M Buy
984,630
+108,191
+12% +$3.7M 0.99% 45
2014
Q1 		$32.3M Buy
876,439
+63,270
+8% +$2.32M 1.14% 33
2013
Q4 		$31.2M Buy
813,169
+732,931
+913% +$23.1M 1.17% 32
2013
Q3 		$2.2M Buy
+80,238
New +$1.9M 0.1% 158

Other funds holding WX

Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
CCS
Crosspoint Capital Strategies Orinda, California $50.4M AUM 15.37% 1-Year Est. Return

Apex Capital Management's WX Position: Q4 2015 in Review

Apex Capital Management sold out of WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS (WX) in Q4 2015, closing a stake of 1,723,714 shares — an estimated $74.5M sold.

Apex Capital Management first reported a position in WX in Q3 2013 and held it in 9 quarters. The position peaked at $74.5M in Q3 2015. 2 funds tracked by Wall St. Rank hold WX as of Q4 2015.

  • Apex Capital Management reported no remaining WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position as of Q4 2015 after selling out during the quarter.
  • Apex Capital Management sold 1,723,714 WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS shares in Q4 2015, an estimated $74.5M.
  • Apex Capital Management first reported a position in WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS in Q3 2013 and held it in 9 quarters.
  • Apex Capital Management's WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position peaked at $74.5M in Q3 2015.
  • 2 funds tracked by Wall St. Rank held WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS as of Q4 2015.

Based on Apex Capital Management's 13F filing for Q4 2015, filed 20 Jan 2016.